Optimal management of hormone receptor positive metastatic breast cancer in 2016 - Wikidata - awgldk - TriplyDB

Optimal management of hormone receptor positive metastatic breast cancer in 2016

Optimal management of hormone receptor positive metastatic breast cancer in 2016

http://www.wikidata.org/entity/Q26777683

about

Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.Confronting the therapeutic misconception.Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Recent Advances in the Treatment of Breast Cancer.Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

P2860

Q33812688-1F092A19-1827-424A-B200-9FF98D8A2B5B Q37699590-7BB73354-4BEF-43D2-9328-AD29CA3C3F56 Q38784119-181ACA45-3981-40F1-8D2D-C222F25225ED Q47169141-27882E25-92C3-4966-9011-A1FE53602740 Q47561979-2D0A1F60-A0BE-46BB-9E38-69EA19596F3A Q49632496-92246479-BF78-4014-B767-37E837C43F29 Q50073288-84AE8B17-2825-4E34-88E2-278818CF2DDF Q55112712-C7BBB2CC-03CE-4941-9B55-B9A048278F9F Q55310990-79993C7A-0A5B-4DE4-9D31-1EB13B97C00B Q55353691-7E0C8F9B-F85D-455C-9B4F-7017F53128A4 Q57108041-FBE6B516-7662-44E0-994E-2921FCBC407F Q57809635-5DE43A42-0CCA-4B56-9451-78B0AAC14669

P2860

Optimal management of hormone receptor positive metastatic breast cancer in 2016

http://www.wikidata.org/entity/Q26777683

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@ast

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@en

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@nl

type

label

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@ast

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@en

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@nl

prefLabel

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@ast

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@en

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@nl

P1433

Q26777683-09EE854C-98C1-459F-964E-4B24B0DBA811

P1476

Q26777683-0591732F-03D3-4380-A50B-B9EB6956A195

P2093

Q26777683-928A9E7B-DB0C-4409-A397-0AF6E38AB8F4

P2860

Q26777683-017308E7-C59A-401C-868C-D82613DABBF7

Q26777683-02891AB8-C8D0-4A0E-83B5-69DF1DDD8CE7

Q26777683-03273646-BA92-4F4A-A43E-C8704156F850

Q26777683-036038FC-AFE4-4835-B9DA-286FD8CDD620

Q26777683-0674513C-97CF-4591-9C3B-04D81F2CF023

Q26777683-0701721F-0A1D-45B4-BD97-13105D49C6F2

Q26777683-07596119-F5BA-4BF6-82D6-57288E6E6839

Q26777683-08203422-8257-4F6C-BCDC-CDEAE7A905B8

Q26777683-0938C6E9-9185-457C-B6DE-62D08A20D978

Q26777683-096237C4-F8F7-46E6-856B-3D5CD490A5A9

P304

Q26777683-5188995C-C94A-44BF-97AE-19F73637015D

P31

Q26777683-AB52C768-E484-4281-B5E6-D173CA997AD2

P356

Q26777683-20A1F5E4-FF0D-410C-88BF-F7C7F53E727A

P407

Q26777683-866DF74C-35D6-4FD3-9702-D5D2BB701DDB

P433

Q26777683-08B883B6-5652-46CA-93F9-2318EF00B1DA

P478

Q26777683-C9A0113C-584D-492D-A649-78D08025AC36

P50

Q26777683-EF8ED767-5510-470A-AABC-661AF71B4BAE

P577

Q26777683-C5BD39EA-564D-4BF4-94A1-5BDD6837F1A9

P5875

Q26777683-377558EF-6EDE-4654-86B1-CBC275153BDE

P698

Q26777683-A63B4742-CA0A-4C0C-B365-184A53DF9473

P932

Q26777683-B970AF9F-4968-4180-ABBF-7007CDD03298

P356

1758834015608993

P1433

Therapeutic advances in medical oncology

P1476

Optimal management of hormone receptor positive metastatic breast cancer in 2016

@en

P2093

Carlos H Barrios

http://www.w3.org/2001/XMLSchema#string

P2860

A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474

Combination anastrozole and fulvestrant in metastatic breast cancer

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts

Comprehensive molecular portraits of human breast tumours

The sequential use of endocrine treatment for advanced breast cancer: where are we?

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

P304

304-320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834015608993

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283485226

http://www.w3.org/2001/XMLSchema#string

P698

26557899

http://www.w3.org/2001/XMLSchema#string

P932

4622303

http://www.w3.org/2001/XMLSchema#string